FDA Oncology Products Office Reorganization Keeps Leadership Intact
Executive Summary
Restructuring of FDA's oncology product review divisions will not include an upheaval in leadership
You may also be interested in...
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OOP
Agency reorganizes cancer drug reviews by disease type, while keeping leadership, as expected. After scheduled actions, applications will be migrating to their designated areas within the renamed Office of Hematology and Oncology Products.